FDA Submission Update for Bosentan by Zydus Pharms
Zydus Pharms has submitted a supplemental application for Bosentan under ANDA207760, currently under standard review.
Published: July 26, 2026
Updated: July 26, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Endothelin Receptor Antagonist
Asset: Bosentan
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Bosentan
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The submission of a supplemental application for Bosentan by Zydus Pharms signals a potential shift in the competitive landscape for treatments of pulmonary arterial hypertension. This could affect pricing strategies and market share for existing players in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review timeline and any updates on approval status from the FDA.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.